// Questa è una singola drug, presa dal file "drugbank.xml", cioè tutto ciò che va dal primo <drugbank-id> fino al rigo prima del secondo

<drugbank-id>DB00001</drugbank-id>asding!
    <name>Lepirudin</name>
    <description>Lepirudin is identical to natural hirudin except for substitution of leucine for isoleucine at the N-terminal end of the molecule and the absence of a sulfate group on the tyrosine at position 63. It is produced via yeast cells.&#xD;
</description>
    <cas-number>120993-53-5</cas-number>
    <general-references># Smythe MA, Stephens JL, Koerber JM, Mattson JC: A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Hemost. 2005 Oct;11(4):371-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16244762&#xD;
# Tardy B, Lecompte T, Boelhen F, Tardy-Poncet B, Elalamy I, Morange P, Gruel Y, Wolf M, Francois D, Racadot E, Camarasa P, Blouch MT, Nguyen F, Doubine S, Dutrillaux F, Alhenc-Gelas M, Martin-Toutain I, Bauters A, Ffrench P, de Maistre E, Grunebaum L, Mouton C, Huisse MG, Gouault-Heilmann M, Lucke V: Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood. 2006 Sep 1;108(5):1492-6. Epub 2006 May 11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16690967&#xD;
# Lubenow N, Eichler P, Lietz T, Greinacher A: Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost. 2005 Nov;3(11):2428-36. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16241940&#xD;
# Askari AT, Lincoff AM: Antithrombotic Drug Therapy in Cardiovascular Disease. 2009 Oct; pp. 440&#x2013;. ISBN 9781603272346. "Google books":http://books.google.com/books?id=iadLoXoQkWEC&amp;pg=PA440. </general-references>
    <synthesis-reference></synthesis-reference>
    <indication>For the treatment of heparin-induced thrombocytopenia</indication>
    <pharmacology>Lepirudin is used to break up clots and to reduce thrombocytopenia. It binds to thrombin and prevents thrombus or clot formation. It is a highly potent, selective, and essentially irreversible inhibitor of thrombin and clot-bond thrombin. Lepirudin requires no cofactor for its anticoagulant action. Lepirudin is a recombinant form of hirudin, an endogenous anticoagulant found in medicinal leeches.</pharmacology>
    <mechanism-of-action>Lepirudin forms a stable non-covalent complex with alpha-thrombin, thereby abolishing its ability to cleave fibrinogen and initiate the clotting cascade. The inhibition of thrombin prevents the blood clotting cascade. </mechanism-of-action>
    <toxicity>In case of overdose (eg, suggested by excessively high aPTT values) the risk of bleeding is increased.</toxicity>
    <biotransformation>Lepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the parent drug. However, con-clusive data are not available. About 48% of the administration dose is excreted in the urine which consists of unchanged drug (35%) and other fragments of the parent drug.</biotransformation>
    <absorption>Bioavailability is 100% following injection.</absorption>
    <half-life>Approximately 1.3 hours</half-life>
    <protein-binding></protein-binding>
    <route-of-elimination>Lepirudin is thought to be metabolized by release of amino acids via catabolic hydrolysis of the parent drug. About 48% of the administration dose is excreted in the urine which consists of unchanged drug (35%) and other fragments of the parent drug.</route-of-elimination>
    <volume-of-distribution>* 12.2 L [Healthy young subjects (n = 18, age 18-60 years)]&#xD;
* 18.7 L [Healthy elderly subjects (n = 10, age 65-80 years)]&#xD;
* 18 L [Renally impaired patients (n = 16, creatinine clearance below 80 mL/min)]&#xD;
* 32.1 L [HIT patients (n = 73)]</volume-of-distribution>
    <clearance>* 164 ml/min [Healthy 18-60 yrs]&#xD;
* 139 ml/min [Healthy 65-80 yrs]&#xD;
* 61 ml/min [renal impaired]&#xD;
* 114 ml/min [HIT (Heparin-induced thrombocytopenia)]</clearance>
    <secondary-accession-numbers>
      <secondary-accession-number>BIOD00024</secondary-accession-number>
      <secondary-accession-number>BTD00024</secondary-accession-number>
    </secondary-accession-numbers>
    <groups>
      <group>approved</group>
    </groups>
    <taxonomy>
      <kingdom></kingdom>
    </taxonomy>
    <synonyms>
      <synonym>Hirudin variant-1</synonym>
    </synonyms>
    <salts/>
    <brands>
      <brand>Refludan</brand>
    </brands>
    <mixtures/>
    <packagers>
      <packager>
        <name>Bayer Healthcare</name>
        <url>http://www.bayerhealthcare.com</url>
      </packager>
      <packager>
        <name>Berlex Labs</name>
        <url>http://www.berlex.com</url>
      </packager>
    </packagers>
    <manufacturers>
      <manufacturer generic="false">Bayer healthcare pharmaceuticals inc</manufacturer>
    </manufacturers>
    <prices>
      <price>
        <description>Refludan 50 mg vial</description>
        <cost currency="USD">273.19</cost>
        <unit>vial</unit>
      </price>
    </prices>
    <categories>
      <category>Anticoagulants</category>
      <category>Antithrombotic Agents</category>
      <category>Fibrinolytic Agents</category>
    </categories>
    <affected-organisms>
      <affected-organism>Humans and other mammals</affected-organism>
    </affected-organisms>
    <dosages>
      <dosage>
        <form>Powder, for solution</form>
        <route>Intravenous</route>
        <strength></strength>
      </dosage>
    </dosages>
    <atc-codes>
      <atc-code>B01AE02</atc-code>
    </atc-codes>
    <ahfs-codes>
      <ahfs-code>20:12.04.12</ahfs-code>
    </ahfs-codes>
    <patents>
      <patent>
        <number>5180668</number>
        <country>United States</country>
        <approved>1993-01-19</approved>
        <expires>2010-01-19</expires>
      </patent>
      <patent>
        <number>1339104</number>
        <country>Canada</country>
        <approved>1997-07-29</approved>
        <expires>2014-07-29</expires>
      </patent>
    </patents>
    <food-interactions/>
    <drug-interactions>
      <drug-interaction>
        <drug>DB01381</drug>
        <name>Ginkgo biloba</name>
        <description>Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.</description>
      </drug-interaction>
      <drug-interaction>
        <drug>DB00374</drug>
        <name>Treprostinil</name>
        <description>The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Lepirudin. Monitor for increased bleeding during concomitant thearpy. </description>
      </drug-interaction>
    </drug-interactions>
    <protein-sequences>
      <protein-sequence>
        <header>DB00001 sequence</header>
        <chain>LVYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIPEEYLQ</chain>
      </protein-sequence>
    </protein-sequences>
    <experimental-properties>
      <property>
        <kind>logP/hydrophobicity</kind>
        <value>-0.777</value>
        <source></source>
      </property>
      <property>
        <kind>Molecular Weight</kind>
        <value>6963.4250</value>
        <source></source>
      </property>
      <property>
        <kind>Molecular Formula</kind>
        <value>C287H440N80O110S6</value>
        <source></source>
      </property>
    </experimental-properties>
    <external-identifiers>
      <external-identifier>
        <resource>Drugs Product Database (DPD)</resource>
        <identifier>2240996</identifier>
      </external-identifier>
      <external-identifier>
        <resource>National Drug Code Directory</resource>
        <identifier>50419-150-57</identifier>
      </external-identifier>
      <external-identifier>
        <resource>PharmGKB</resource>
        <identifier>PA450195</identifier>
      </external-identifier>
      <external-identifier>
        <resource>UniProtKB</resource>
        <identifier>P01050</identifier>
      </external-identifier>
    </external-identifiers>
    <external-links>
      <external-link>
        <resource>Wikipedia</resource>
        <url>http://en.wikipedia.org/wiki/Lepirudin</url>
      </external-link>
      <external-link>
        <resource>RxList</resource>
        <url>http://www.rxlist.com/cgi/generic/lepirudin.htm</url>
      </external-link>
      <external-link>
        <resource>Drugs.com</resource>
        <url>http://www.drugs.com/cdi/lepirudin.html</url>
      </external-link>
    </external-links>
    <targets>
      <target partner="54">
        <actions>
          <action>inhibitor</action>
        </actions>
        <references># Turpie AG: Anticoagulants in acute coronary syndromes. Am J Cardiol. 1999 Sep 2;84(5A):2M-6M. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10505536&#xD;
# Warkentin TE: Venous thromboembolism in heparin-induced thrombocytopenia. Curr Opin Pulm Med. 2000 Jul;6(4):343-51. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10912644&#xD;
# Eriksson BI: New therapeutic options in deep vein thrombosis prophylaxis. Semin Hematol. 2000 Jul;37(3 Suppl 5):7-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11055889&#xD;
# Fabrizio MC: Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass. J Extra Corpor Technol. 2001 May;33(2):117-25. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11467439&#xD;
# Szaba FM, Smiley ST: Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood. 2002 Feb 1;99(3):1053-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11807012&#xD;
# Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
        <known-action>yes</known-action>
      </target>
    </targets>
    <enzymes/>
    <transporters/>
    <carriers/>
  </drug>
  <drug type="biotech" created="2005-06-13 07:24:05 -0600" updated="2011-07-31 23:04:49 -0600" version="3.0">
